4,835 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Stonehaven Wealth & Tax Solutions LLC

Stonehaven Wealth & Tax Solutions LLC acquired a new stake in Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 4,835 shares of the biopharmaceutical company’s stock, valued at approximately $273,000.

Several other large investors have also made changes to their positions in BMY. Norges Bank bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $1,989,525,000. Wellington Management Group LLP boosted its position in shares of Bristol-Myers Squibb by 3,880.0% in the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company’s stock worth $338,088,000 after purchasing an additional 5,827,317 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $257,618,000. Schroder Investment Management Group boosted its holdings in Bristol-Myers Squibb by 49.7% during the fourth quarter. Schroder Investment Management Group now owns 11,413,428 shares of the biopharmaceutical company’s stock worth $639,837,000 after buying an additional 3,787,075 shares during the last quarter. Finally, Independent Franchise Partners LLP grew its position in shares of Bristol-Myers Squibb by 20.8% during the 4th quarter. Independent Franchise Partners LLP now owns 17,129,229 shares of the biopharmaceutical company’s stock worth $968,829,000 after buying an additional 2,944,879 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Buying and Selling

In other news, EVP Samit Hirawat acquired 1,823 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.07% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Down 2.7 %

Shares of BMY stock opened at $49.98 on Wednesday. The firm’s fifty day moving average price is $57.39 and its two-hundred day moving average price is $56.73. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The firm has a market capitalization of $101.70 billion, a P/E ratio of -11.31, a PEG ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, equities analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.96%. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BMY shares. UBS Group reduced their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research note on Friday, April 11th. Cantor Fitzgerald lifted their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Finally, Citigroup boosted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $57.67.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.